Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+advanced gastric or gastroesophageal junction adenocarcinoma

被引：3
|
作者：
Shitara, Kohei
Bang, Yung-Jue
Iwasa, Satoru
Sugimoto, Naotoshi
Ryu, Min-Hee
Sakai, Daisuke
Chung, Hyun Cheol Cheol
Omuro, Yasushi
Kawakami, Hisato
Yabusaki, Hiroshi
Sakamoto, Yasuhiro
Nishina, Tomohiro
Inaki, Koichiro
Kuwahara, Yusuke
Suto, Fumitaka
Sugihara, Masahiro
Saito, Kaku
Kojima, Akihito
Yamaguchi, Kensei
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Seoul Natl Univ, Coll Med, Seoul, South Korea
[3] Natl Canc Ctr, Tokyo, Japan
[4] Osaka Int Canc Inst, Osaka, Japan
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[6] Osaka Univ Hosp, Osaka, Japan
[7] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[8] Tokyo Metropolitan Komagome Hosp, Tokyo, Japan
[9] Kindai Univ Hosp, Osaka, Japan
[10] Niigata Canc Ctr Hosp, Niigata, Japan
[11] Osaki Citizen Hosp, Osaki, Miyagi, Japan
[12] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[13] Daiichi Sankyo, Tokyo, Japan
[14] Daiichi Sankyo, Basking Ridge, NJ USA
[15] JFCR, Canc Inst Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.322
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
322
引用
收藏
页数：3
相关论文
共 34 条
  • [1] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
    Yamaguchi, K.
    Bang, Y.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M.
    Sakai, D.
    Chung, H.
    Kawakami, H.
    Yabusaki, H.
    Lee, J.
    Saito, K.
    Kawaguchi, Y.
    Kamio, T.
    Kojima, A.
    Sugihara, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S235 - S235
  • [2] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-hee
    Sakai, Daisuke
    Chung, Hyun Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
    Yamaguchi, K.
    Bang, Y-J.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M-H.
    Sakai, D.
    Chung, H. C.
    Kawakami, H.
    Yabusaki, H.
    Lee, J.
    Saito, K.
    Kawaguchi, Y.
    Kamio, T.
    Kojima, A.
    Sugihara, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S899 - S900
  • [4] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01)
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun Cheol Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [5] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun Cheol Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma
    Shitara, K.
    Bang, Y.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M.
    Sakai, D.
    Chung, H.
    Omuro, Y.
    Kawakami, H.
    Yabusaki, H.
    Sakamoto, Y.
    Nishina, T.
    Inaki, K.
    Kuwahara, Y.
    Suto, F.
    Sugihara, M.
    Saito, K.
    Kojima, A.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S224 - S224
  • [7] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
    Siena, Salvatore
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Fakih, Marwan
    Elez, Elena
    Rodriguez, Javier
    Ciardiello, Fortunato
    Saxena, Kapil
    Yamamoto, Eriko
    Bako, Emarjola
    Okuda, Yasuyuki
    Shahidi, Javad
    Grothey, Axel
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
    Siena, S.
    Raghav, K.
    Masuishi, T.
    Yamaguchi, K.
    Nishina, T.
    Elez, E.
    Rodriguez, J.
    Chau, I.
    Di Bartolomeo, M.
    Kawakami, H.
    Suto, F.
    Kobayashi, K.
    Koga, M.
    Inaki, K.
    Kuwahara, Y.
    Takehara, I.
    Grothey, A.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S532 - S532
  • [9] A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Fuchs, C.
    Shahidi, J.
    Mathew, L.
    Qin, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S150 - S150
  • [10] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01
    Yoshino, T.
    Siena, S.
    Di Bartolomeo, M.
    Raghav, K.
    Masuishi, T.
    Loupakis, F.
    Kawakami, H.
    Yamaguchi, K.
    Nishina, T.
    Fakih, M.
    Elez, E.
    Rodriguez, J.
    Ciardiello, F.
    Saxena, K.
    Yamamoto, E.
    Kobayashi, K.
    Bako, E.
    Okuda, Y.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1275 - S1275
1234